Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria

A major worldwide concern, antimicrobial resistance (AMR) is expected to kill 10 million people a year by 2050. Antibiotics are losing their effectiveness, which has a negative impact on health and the economy. Despite the pressing demand, the development of antibiotics is hampered by scientific, financial, and regulatory issues, which forces large corporations to leave the market. The AMR dilemma, the difficulties in developing antibiotics, especially for Gram-negative bacteria, and possible ways to revive the antibiotic pipeline are all covered in this paper.